2021ADA Hot Spots | "Insulin glargine U300" brings a number of blockbuster studies to the world!

At the 81st ADA Annual Conference, cutting-edge research in the field of diabetes will also be unveiled.

As a new generation of basal insulin analogue, insulin glargine U300 has a new subcutaneous storage microprecipitation technology, so the glucose control effect is longer and more stable.

What is the efficacy and safety of insulin glargine U300 in the real world?

A study on the combined use of insulin glargine U300 and glucagon-like peptide-1 receptor agonist (GLP-1RA)—the results of the DELIVER-G study will be announced at this annual meeting

It is also worth noting that the ARTEMIS-DM study of patients with diabetes in many countries and regions is included, and its coverage includes Hong Kong, India, Indonesia, Malaysia, Philippines, Thailand in Asia, Argentina, Peru, Colombia in Latin America, and the Middle East and Africa.

What is the "real" performance of insulin glargine U300 in a wider range of special populations?

As we all know, the BRIGHT study subgroup analysis1,2 explored the efficacy and safety of insulin glargine U300 in elderly or T2DM patients with renal insufficiency, and obtained gratifying results

Another subgroup analysis of the ATOS study conducted an in-depth exploration of the efficacy of insulin glargine U300 and the risk of hypoglycemia for patients with different baseline glycosylated hemoglobin (HbA1c) levels

So how does insulin glargine U300 perform in patients with type 1 diabetes (T1DM)? A study released at this ADA annual meeting will bring the answer! The study used the European authoritative real-world database for research design, and was intended to explore the efficacy of insulin glargine U300 in the treatment of T1DM in a clinical practice environment (insulin glargine U300 has been approved by EMA and FDA and can be used in adults, children 6 years and older and Adolescents with T1DM to control blood sugar levels)

The release of the above research results is believed to provide strong evidence-based support for the application of insulin glargine U300 in a wider range of people!

Insulin glargine U300 VS.

Another large retrospective real-world study using the US Optum Clinformatics claims database is intended to explore the conversion from basal insulin (NPH, insulin detemir, insulin glargine U100) to two groups of insulin (one group converted to insulin glargine U300, The other group converted to insulin glargine (U100 or insulin detemir) after treatment with differences in durability, compliance, medical resource utilization and cost

In short, at this ADA annual meeting, the latest research on insulin glargine U300 covers many aspects of concern in the clinical diagnosis and treatment of diabetes, from the exploration of curative effects in a wider area to the real "performance" of special populations, from different insulins Discovering the difference in treatment and then exploring the medical cost in the real world, I believe this research feast brought by insulin glargine U300 will make you "feast your eyes"!

references

1.

2.

3.

4.